Home/Pipeline/Undisclosed Stem Cell-Derived Therapies

Undisclosed Stem Cell-Derived Therapies

Not Disclosed

Pre-clinicalActive

Key Facts

Indication

Not Disclosed

Phase

Pre-clinical

Status

Active

Company

Stately Bio

About Stately Bio

Stately Bio is a private, preclinical-stage biotech founded in 2021 and based in San Diego. The company has developed a patented AI/ML imaging platform that enables non-destructive, continuous analysis of live cells, aiming to overcome the traditional trade-off between measurement and cell viability. This technology serves a dual purpose: powering internal discovery of novel stem cell-derived therapies and providing a platform for external R&D partnerships with leading institutions. Stately Bio operates at the intersection of AI-driven biotech tools and regenerative medicine therapeutics.

View full company profile

Therapeutic Areas

Regenerative Medicine

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active